Amgen Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for AMGN, updated each market day.
AMGN AI Sentiment
AI sees no strong directional signal for Amgen Inc stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Sector
Exchange
Market Cap
$187,929,772,858
Cap Tier
Employees
31,500
Headquarters
THOUSAND OAKS, CA
Listed Since
June 17, 1983
Website
AMGN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AMGN Volatility
Amgen Inc has shown low price volatility over the last 5 trading days. Low volatility suggests steady price action with smaller daily moves.
